

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN).

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 12 to 60 years old - diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to starting the study for adults and within 3 years for adolescents - must have a vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment - see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria

Exclusion Criteria:

- have had cell or a solid organ transplantation, including kidney transplantation - Body mass index (BMI) >38 kg/m² - Body weight <35 kg (77 pounds) - additional criteria that study staff will review

Conditions & Interventions

Keywords:

Clinics and Surgery Center (CSC), Glomerulonephritis, IC-MPGN

More Information

Description: To evaluate the efficacy and safety of iptacopan compared to placebo in patients with idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)

Study Contact: Nattawat Klomjit - klomj001@umn.edu

Principal Investigator: Nattawat Klomjit

IRB

Number: STUDY00020504

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.